Serina Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	24.53	3.06	3.67	7.62	0.65	0.58
Cash & Short-Term Investments	24.53	3.06	3.67	7.62	0.65	0.58
Cash Growth	474.78%	-16.78%	-51.80%	1081.24%	10.45%	10.82%
Accounts Receivable	-	-	-	-	0	0.03
Total Current Assets	24.53	3.06	3.67	7.62	0.65	0.61
Total Assets	24.53	3.06	3.67	7.62	0.65	0.61
Other Current Liabilities	1.55	-	-	-	-	-
Total Current Liabilities	1.55	-	-	-	-	-
Total Liabilities	1.55	-	-	-	-	-
Preferred Stock	4.94	4.94	-	-	-	-
Shareholders' Equity	4.94	4.94	-	-	-	-
Total Liabilities & Equity	6.49	4.94	-	-	-	-
Net Cash (Debt)	24.53	3.06	3.67	7.62	0.65	0.58
Net Cash Growth	702.55%	-16.78%	-51.80%	1081.24%	10.45%	10.82%
Net Cash Per Share	2.28	0.30	0.50	1.04	0.30	0.54
Book Value	4.94	4.94	0	0	0	0
Book Value Per Share	0.46	0.48	-	-	-	-
Tangible Book Value	4.94	4.94	0	0	0	0
Tangible Book Value Per Share	0.46	0.48	-	-	-	-

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q